Zensar Technologies acquires BridgeView Life Sciences to enhance healthcare solutions

In a significant move within the technology and healthcare sectors, Zensar Technologies, an RPG Group Company based in Pune, has announced the complete acquisition of BridgeView Life Sciences LLC. This acquisition marks a strategic expansion of Zensar’s capabilities in the Healthcare and Life Sciences (HLS) sectors, notably enhancing its pharmaceutical commercial and product launch expertise. The financial details of the acquisition were not disclosed.

BridgeView Life Sciences, headquartered in the United States, is renowned for its extensive advisory, transformation, and managed services tailored specifically for life sciences companies. These services are crucial for organizations looking to launch products, optimize operations, or navigate mergers and acquisitions. Through this acquisition, Zensar not only broadens its service offering but also solidifies its standing as a preferred technology partner in the life sciences sector.

The acquisition by Zensar introduces a more robust suite of solutions targeted at pharmaceutical, biotechnology, and medical device companies. BridgeView holds prestigious statuses such as “Preferred Services Partner” and “Services Partner” with Veeva Systems in their Commercial Cloud and Development Cloud platforms, respectively. Additionally, partnerships with industry leaders like Reltio, Datavant, Snowflake, Salesforce, and IQVIA enhance BridgeView’s and now Zensar’s capabilities significantly.

Anant Goenka, Vice‐Chairman of RPG Enterprises and Zensar Technologies, emphasized the strategic nature of this acquisition, stating, “Acquiring BridgeView Life Sciences aligns with our long‐term growth strategy for our growing HLS practice. It deepens our services for existing clients and expands into new areas, especially for innovators and emerging pharma players underserved by technology.”

Manish Tandon, CEO and Managing Director of Zensar Technologies, commented on the acquisition’s alignment with Zensar’s vision: “BridgeView Life Sciences brings a team of seasoned professionals with deep life sciences knowledge and a successful track record. This enhances our HLS offerings and accelerates our go‐to‐market strategy, establishing us as a leader in this space.”

James Corbett and Mihales Karasavas, Co-founders of BridgeView Life Sciences, expressed their enthusiasm about joining Zensar. They highlighted the potential for broader solution offerings and an expanded audience reach, which will effectively improve patient outcomes and expedite transformational programs in the life sciences sector.

This acquisition positions Zensar as a pivotal force in driving innovation and facilitating the digital transformation of life sciences companies. As the industry faces ongoing challenges, the enhanced capabilities and expanded expertise brought by BridgeView are expected to play a crucial role in advancing Zensar’s market presence and efficacy in delivering critical healthcare solutions.